Stock screener

RGNX

Conviction 73HealthcareScan · Fri, Jul 17, 2026
RGNX$9.87-11.92%
ResistanceSupportVol 14Insider sell
63 bars
Vol MA14 3.42M
Apr 17May 5May 22Jun 10Jun 30Jul 17
REGENXBIO Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.regenxbio.com
Price9.87
Change-11.92%
Gap-20.18%
Rel volume5.02×
Avg volume3.57M
Avg $ vol40.65M
SMA 2012.04
SMA 509.17
SMA 20010.61
Price vs 50+7.63%
Price vs 200-7.03%
MA stackmixed
50/200 cross
Supertrenddown · 13.32
RSI (14)42
MACD hist-0.47
MACD crossbear · 2d
Stoch %K / %D19 / 27
ADX (14)38
+DI / −DI22 / 35
RSI divergence
MACD divergence
ATR %+12.44%
ADR %10.48%
52w high15.98
52w low5.65
From 52w high-38.27%
Above 52w low+74.60%
New 52w highNo
SqueezeOff
Bollinger width71.81%
%B0.25
Donchian pos25.74%
Donchian high15.88
Donchian low7.78
AVWAP (52w high)9.40
vs AVWAP high+4.93%
AVWAP (52w low)9.67
vs AVWAP low+2.06%
OBV trendUp
Chaikin MF (20)0.14
Today vs 20d5.02×
Avg vol (14d)3.42M
Avg vol (20d)3.57M
Avg $ vol (20d)40.65M
Market cap510M
RS 3m (vs SPY)+12.40%
RS 6m (vs SPY)-33.79%
RS line new highNo
Trend template4/8
Technical rank39.9
1 week-29.28%
1 month+42.35%
3 months+7.34%
6 months-34.01%
1 year+16.06%
YTD-27.30%
P/E-2.63
P/B24.19
P/S2.99
P/FCF-4.04
EPS-3.76
Div yield
ROE-919.64%
ROA-56.71%
Debt/Eq
Current2.62
EV/EBITDA-3.40
Gross margin
Net margin-113.75%
Rev growth104.54%
EPS growth14.63%
Price target20.89
Target upside111.76%
Analyst ratingBuy
Institutional87.29%
Ent. value494.77M
Revenue6.39M
Net income-90.05M
Gross profit
Free cash flow-126.38M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out51.7M
Employees371
ListedThu, Sep 17, 2015
Free float38.66M
Float %74.9%
Short interest10.46M
Days to cover3.2d
Short volume26.4%
Squeeze score71 / 100
Next earnings
EPS forecast
Last EPS vs est−$1.72 vs −$1.36
Last surprise-26.5% miss
Setup gradeB
Conviction73 / 100
Pattern quality
Tech rank39.9 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction
Pattern family
Resistance13.43
Support5.92
Days since event
Candle confirm
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in RGNX

All disclosures →
No recent disclosed trades by Congress in RGNX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in RGNX · 10 buys

InsiderSideShares
Bennett Jean
Director · Stock Options (Right to Buy) · 2026-05-29
Grant46.6K
Tasse Daniel
Director · Common Stock · 2026-05-29
Grant9.81K
Zachary Jennifer
Director · Stock Options (Right to Buy) · 2026-05-29
Grant46.6K
Glucksmann Alexandra
Director · Stock Options (Right to Buy) · 2026-05-29
Grant46.6K
KARABELAS ARGERIS N
Director · Common Stock · 2026-05-29
Grant9.81K
Glucksmann Alexandra
Director · Common Stock · 2026-05-29
Grant9.81K
Tasse Daniel
Director · Stock Options (Right to Buy) · 2026-05-29
Grant46.6K
Zachary Jennifer
Director · Common Stock · 2026-05-29
Grant9.81K
Fox Allan M.
Director · Stock Options (Right to Buy) · 2026-05-29
Grant46.6K
KARABELAS ARGERIS N
Director · Stock Options (Right to Buy) · 2026-05-29
Grant46.6K

SEC filings

EDGAR filings in RGNX · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.